Japanese winners of U.S. Lasker Award

TOKYO, Japan, Sept. 10 Kyodo - Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. attend a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia. (Kyodo)

Japanese winner of U.S. Lasker Award

Japanese winner of U.S. Lasker Award

Japanese researcher Takehisa Kitazawa of Chugai Pharmaceutical Co. attends a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research. Kitazawa shared the award with fellow Chugai researchers Kunihiro Hattori and Tomoyuki Igawa for their contributions to the development of a treatment for hemophilia.

Japanese winner of U.S. Lasker Award

Japanese winner of U.S. Lasker Award

Japanese researcher Tomoyuki Igawa of Chugai Pharmaceutical Co. attends a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research. Kitazawa shared the award with fellow Chugai researchers Kunihiro Hattori and Takehisa Kitazawa for their contributions to the development of a treatment for hemophilia.

Japanese winner of U.S. Lasker Award

Japanese winner of U.S. Lasker Award

Japanese researcher Kunihiro Hattori of Chugai Pharmaceutical Co. attends a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research. Hattori shared the award with fellow Chugai researchers Takehisa Kitazawa and Tomoyuki Igawa for their contributions to the development of a treatment for hemophilia.

Japanese winners of U.S. Lasker Award

Japanese winners of U.S. Lasker Award

(From L) Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. pose for a photo during a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia.

Japanese winners of U.S. Lasker Award

Japanese winners of U.S. Lasker Award

(From L) Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. pose for a photo during a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia.

Japanese winners of U.S. Lasker Award

Japanese winners of U.S. Lasker Award

(From L) Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. pose for a photo during a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia.

Japanese winners of U.S. Lasker Award

Japanese winners of U.S. Lasker Award

(From L) Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. attend a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia.

Japanese winners of U.S. Lasker Award

Japanese winners of U.S. Lasker Award

(From L) Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. attend a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia.

Japanese winners of U.S. Lasker Award

Japanese winners of U.S. Lasker Award

(From L) Japanese researchers Takehisa Kitazawa, Kunihiro Hattori and Tomoyuki Igawa of Chugai Pharmaceutical Co. attend a press conference in Tokyo on Sept. 10, 2026, after receiving the Lasker Award for clinical medical research for their contributions to the development of a treatment for hemophilia.

Chugai Pharmaceutical signage and logo

Chugai Pharmaceutical signage and logo

Chugai Pharmaceutical signage and logo =Date:April 9, 2024, Place: Tokyo

Chugai Pharmaceutical signage and logo

Chugai Pharmaceutical signage and logo

Chugai Pharmaceutical signage and logo =Date:April 9, 2024, Place: Tokyo

500 hours achieved in biomass power generation

500 hours achieved in biomass power generation

YAMAGUCHI, Japan - Chugai Ro Co., an Osaka-based industrial furnace manufacturer, succeeded in generating electricity with biomass fuels for 500 consecutive hours, one of the longest records in the world, at a test facility in Yamaguchi, western Japan, company officials said on Feb. 4.

500 hours achieved in biomass power generation

500 hours achieved in biomass power generation

YAMAGUCHI, Japan - Chugai Ro Co., an Osaka-based industrial furnace manufacturer, succeeded in generating electricity with biomass fuels for 500 consecutive hours, one of the longest records in the world, at a test facility in Yamaguchi, western Japan, company officials said on Feb. 4. (Kyodo)

Japan suspends use of anti-flu drug Tamiflu for teens

Japan suspends use of anti-flu drug Tamiflu for teens

TOKYO, Japan - The anti-flu drug Tamiflu, wrapped in packages sold in Japan. (File photo) The drug, manufactured by Roche Holding AG of Switzerland, is imported and sold in Japan by Chugai Pharmaceutical Co. The Japanese health ministry announced March 21 that the government has recommended against the use of the anti-flu drug Tamiflu among teenagers. (Kyodo)